Literature DB >> 26280402

Evidence-based recommendations of postoperative radiotherapy in lung cancer from Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).

A Gómez1, J A González2, F Couñago3, C Vallejo4, F Casas5, N Rodríguez de Dios6,7,8.   

Abstract

Locally advanced non-small cell lung cancer (NSCLC) is a diversified illness in which postoperative radiation therapy (PORT) for complete resection with positive hiliar (pN1) and/or mediastinal (pN2) lymph nodes is controversial. Although several studies have shown that PORT has beneficial effects, randomized trials are needed to demonstrate its impact on overall survival. In this review, the Spanish Radiation Oncology Group for Lung Cancer describes the most relevant literature on PORT in NSCLC patients stage pN1-2. In addition, we have outlined the current recommendations of different national and international clinical guidelines and have also specified practical issues regarding treatment volume definition, doses and fractionation.

Entities:  

Keywords:  Adjuvant treatment; Non-small cell lung cancer; Pathologic N2; Postoperative radiation therapy

Mesh：

Year:  2015        PMID： 26280402     DOI： 10.1007/s12094-015-1374-z

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  52 in total

1.  A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group.

Authors:  S M Keller; S Adak; H Wagner; A Herskovic; R Komaki; B J Brooks; M C Perry; R B Livingston; D H Johnson
Journal:  N Engl J Med       Date:  2000-10-26       Impact factor: 91.245

2.  The impact of surgical adjuvant thoracic radiation therapy for patients with nonsmall cell lung carcinoma with ipsilateral mediastinal lymph node involvement.

Authors:  T E Sawyer; J A Bonner; P M Gould; R L Foote; C Deschamps; V F Trastek; P C Pairolero; M S Allen; E G Shaw; R S Marks; S Frytak; C M Lange; H Li
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

3.  A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Groupe d'Etude et de Traitement des Cancers Bronchiques.

Authors:  B Dautzenberg; R Arriagada; A B Chammard; A Jarema; M Mezzetti; K Mattson; J L Lagrange; C Le Pechoux; B Lebeau; C Chastang
Journal:  Cancer       Date:  1999-07-15       Impact factor: 6.860

4.  Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database.

Authors:  Brian E Lally; Daniel Zelterman; Joseph M Colasanto; Bruce G Haffty; Frank C Detterbeck; Lynn D Wilson
Journal:  J Clin Oncol       Date:  2006-06-12       Impact factor: 44.544

5.  Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590.

Authors:  Heather A Wakelee; Patricia Stephenson; Steven M Keller; Henry Wagner; Arnold Herskovic; Ritsuko Komaki; Randolph S Marks; Michael C Perry; Robert B Livingston; David H Johnson
Journal:  Lung Cancer       Date:  2005-01-05       Impact factor: 5.705

6.  Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.

Authors:  M Overgaard; P S Hansen; J Overgaard; C Rose; M Andersson; F Bach; M Kjaer; C C Gadeberg; H T Mouridsen; M B Jensen; K Zedeler
Journal:  N Engl J Med       Date:  1997-10-02       Impact factor: 91.245

7.  Patterns of local-regional failure in completely resected stage IIIA(N2) non-small cell lung cancer cases: implications for postoperative radiation therapy clinical target volume design.

Authors:  Wen Feng; Xiao-Long Fu; Xu-Wei Cai; Huan-Jun Yang; Kai-Liang Wu; Min Fan; Jia-Qing Xiang; Ya-Wei Zhang; Hai-Quan Chen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-02-11       Impact factor: 7.038

8.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

9.  Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung.

Authors: 
Journal:  N Engl J Med       Date:  1986-11-27       Impact factor: 91.245

10.  Risk factors for locoregional recurrence in patients with resected N1 non-small cell lung cancer: a retrospective study to identify patterns of failure and implications for adjuvant radiotherapy.

Authors:  Chengcheng Fan; Shugeng Gao; Zhouguang Hui; Jun Liang; Jima Lv; Xiaozhen Wang; Jie He; Luhua Wang
Journal:  Radiat Oncol       Date:  2013-12-09       Impact factor: 3.481
View more
  2 in total

1.  Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer.

Authors:  M Majem; J Hernández-Hernández; F Hernando-Trancho; N Rodríguez de Dios; A Sotoca; J C Trujillo-Reyes; I Vollmer; R Delgado-Bolton; M Provencio
Journal:  Clin Transl Oncol       Date:  2019-06-06       Impact factor: 3.405

Review 2.  Adjuvant treatment in lung cancer.

Authors:  Begoña Taboada Valladares; Patricia Calvo Crespo; Urbano Anido Herranz; Antonio Gómez Caamaño
Journal:  J Clin Transl Res       Date:  2021-04-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.